{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T14:32:15Z","timestamp":1793284335989,"version":"4.5.0"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.ahj.2026.107587","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:56:46Z","timestamp":1787587006000},"page":"107587","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Mavacamten monotherapy in obstructive hypertrophic cardiomyopathy: An integrated analysis of phase 3 clinical trials"],"prefix":"10.1016","volume":"303","author":[{"given":"Iacopo","family":"Olivotto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Garcia-Pavia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuang","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali T.","family":"Owens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"MD","given":"Neal K.","family":"Lakdawala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh","family":"Balaratnam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arteid","family":"Memaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Chen","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milind","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2026.107587_bib0001","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1161\/CIRCULATIONAHA.124.072445","article-title":"Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 128 results from VALOR-HCM","volume":"151","author":"Desai","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2026.107587_bib0002","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2026.107587_bib0003","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1093\/eurheartj\/ehae579","article-title":"Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy","volume":"45","author":"Garcia-Pavia","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2026.107587_bib0004","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/jamacardio.2023.3030","article-title":"Effect of mavacamten on Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy: the EXPLORER-CN randomized clinical trial","volume":"8","author":"Tian","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ahj.2026.107587_bib0005","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ahj.2021.05.007","article-title":"Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy","volume":"239","author":"Desai","year":"2021","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2026.107587_bib0006","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-071473","article-title":"Study design and rationale of EXPLORER-CN: a phase III, randomised, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of mavacamten in Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy","volume":"13","author":"Tian","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.ahj.2026.107587_bib0007","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.125.005502","article-title":"Mavacamten monotherapy in real-world patients with obstructive hypertrophic cardiomyopathy: evidence from COLLIGO-HCM","volume":"19","author":"Bilen","year":"2026","journal-title":"Circ Genom Precis Med"},{"issue":"Suppl_3","key":"10.1016\/j.ahj.2026.107587_bib0008","doi-asserted-by":"crossref","DOI":"10.1161\/circ.152.suppl_3.4365987","article-title":"Abstract 4365987: Real-world outcomes of mavacamten monotherapy in obstructive hypertrophic cardiomyopathy: symptomatic and hemodynamic improvements without increased adverse events","volume":"152","author":"Abraham","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2026.107587_bib0009","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s10741-026-10603-9","article-title":"Evolving strategies in obstructive hypertrophic cardiomyopathy: myosin inhibitors as monotherapy compared with beta-blockers","volume":"31","author":"Grupper","year":"2026","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.ahj.2026.107587_bib0010","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1056\/NEJMoa2504654","article-title":"Aficamten or metoprolol monotherapy for obstructive hypertrophic cardiomyopathy","volume":"393","author":"Garcia-Pavia","year":"2025","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ahj.2026.107587_bib0011","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/j.jacc.2024.09.002","article-title":"Standard-of-care medication withdrawal in patients with obstructive hypertrophic cardiomyopathy receiving aficamten in FOREST-HCM","volume":"84","author":"Masri","year":"2024","journal-title":"JACC"},{"issue":"Supplement_2","key":"10.1016\/j.ahj.2026.107587_bib0012","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehad655.1845","article-title":"Changes in standard of care (SOC) medication during long-term mavacamten treatment for obstructive hypertrophic cardiomyopathy (HCM): results from the EXPLORER cohort of MAVA-Long-Term Extension (LTE)","volume":"44","author":"Lakdawala","year":"2023","journal-title":"Eur Heart J"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870326002498?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870326002498?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T13:35:57Z","timestamp":1793280957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870326002498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":12,"alternative-id":["S0002870326002498"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2026.107587","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mavacamten monotherapy in obstructive hypertrophic cardiomyopathy: An integrated analysis of phase 3 clinical trials","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2026.107587","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107587"}}